Improving Resilience and Equity in Cervical Cancer Screening: Lessons from COVID-19 and Beyond
Agenda
November 9, 2020
|
1:00-1:10 |
Agenda Review and Administrative Statements Administrative remarks, facilitator introduces agenda and process |
|
1:10 – 2:00 |
PCP Working Group Introduction and Presentation PCP introduction, introduce the working team and present work to date on the landscape of opportunities, barriers, and possible solutions |
|
2:00 – 3:00 |
Cervical Cancer Screening Improvement Opportunities Session 1: Prioritize Inclusion of HPV Testing in Screening
|
|
3:00 – 3:15 |
Break |
|
3:15 – 4:15 |
Cervical Cancer Screening Improvement Opportunities Session 2: HPV Self-Sampling to Increase Access for Underserved Populations Opportunities to improve screening, associated barriers, and possible solutions |
|
4:15 – 4:35 |
Working Group Review of Input and Final Comments Review of the day’s stakeholder input and reactions to day’s work |
|
4:35 – 5:00 |
Review of Input and Final Comments Review of the day’s stakeholder input and reactions to day’s work |
November 10, 2020
|
1:00-1:15 |
Agenda Review and Administrative Statements Administrative remarks, facilitator introduces agenda and process, reflections from day 1 |
|
1:15 – 2:15 |
Cervical Cancer Screening Improvement Opportunities Session 3: Using Technology to Improve Screening Management, and Communication with Patients Opportunities to improve screening, associated barriers, and possible solutions |
|
2:15 – 3:15 |
Cervical Cancer Screening Improvement Opportunities Session 4: Risk Based Approach to Screening and Management Opportunities to improve screening, associated barriers, and possible solutions |
|
3:15 – 3:30 |
Break |
|
3:30 – 4:30 |
Cervical Cancer Screening Improvement Opportunities Session 5: Reduce SARs-CoV-2 Infection Risk in Clinical Settings Opportunities to improve screening, associated barriers, and possible solutions |
|
4:30 – 4:40 |
Panel Final Comments Brief review of input and panel discussion of next steps |
|
4:40 – 5:00 |
Response to Public Questions and Comments |